Trial Profile
A clinical study of chimeric-antigen-receptor-tranduced T cells in the treatment of B-cell hematologic malignancies
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Chimeric antigen receptor T cell therapy Hebei Senlang Biotechnology (Primary)
- Indications B-cell leukaemia; B-cell lymphoma; Lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Hebei Senlang Biotechnology
- 26 Apr 2017 New trial record